Thrombolytic Therapy for Acute Myocardial Infarction |
| |
| Authors: | Fred L. Meister Pharm.D. Kathleen A. Stringer Pharm.D. Sarah A. Spinler Pharm.D. Edgar Gonzalez Pharm.D. Robert L. Talbert Pharm.D. Bruce Weiner M.S. FASHP Rawley M. Guerrero Pharm.D. Richard Smith Pharm.D. |
| |
| Affiliation: | 1. School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado;2. Cardiovascular Section, Philadelphia College of Pharmacy and Science, University of Pennsylvania, Philadelphia, Pennsylvania;3. Department of Pharmacy, Medical College of Virginia, Richmond, Virginia;4. Clinical Pharmacy Program, College of Pharmacy, University of Texas-Austin, University of Texas Health Science Center of Texas, San Antonio, Texas;5. Concepts in Healthcare, Inc., Ashland, Massachusetts;6. Department of Pharmacy Services, University of Virginia Medical Center, Charlottesville, Virginia;7. Department of Pharmacy, Green Hospital of Scripps Clinic, La Jolla, California. |
| |
| Abstract: | Numerous factors must be considered when determining the formulary status of thrombolytic agents for the treatment of acute myocardial infarction. Defined treatment options, predicted outcomes, and the economic consequences of this disorder continue to evolve from clinical trials. Pharmacists have a major role in delivering patient care, with responsibility for evaluating, procuring, and monitoring thrombolytic agents and drug therapy in general. By participating in the development and implementation of treatment guidelines, evaluating economic and therapeutic outcomes, providing timely optimal drug therapy, and educating health care providers and the public, they contribute significantly to the health care team. |
| |
| Keywords: | |
|
|
